Elicio Therapeutics shares plunged in morning trading after the company disclosed that its randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P failed to meet the trial's pre-specified primary endpoint. The endpoint was disease-free survival in the intent-to-treat population and the company said the trial did not achieve that metric.
The AMPLIFY-7P study enrolled 144 patients across 24 U.S. sites. It compared treatment with ELI-002 7P to observation after standard locoregional therapy in patients with resected, mutant KRAS-driven pancreatic ductal adenocarcinoma. The program represented Elicio's most advanced and most closely watched clinical asset, and its inability to hit the primary endpoint removed a key near-term regulatory catalyst that had supported the stock's valuation.
In addition to the headline result, Elicio reported a meaningful baseline imbalance between the randomized arms. The company said 19% of patients in the ELI-002 7P arm had R1 resection status, a factor associated with worse prognosis, compared with 10% in the observation arm. That difference prompted questions about the balance achieved by randomization and added to investor concern over the study outcome.
Financial considerations compounded the clinical setback. Management said existing cash resources are expected to fund operations only into the fourth quarter of 2026. The company indicated it is actively exploring strategic financing and partnership options to support the advancement of a potential Phase 3 program. The combination of a failed pivotal-seeming trial, a compressed cash runway and the prospect of dilutive financing created immediate downside pressure on the stock.
Analysts did not uniformly turn bearish in response to the news. Both Rodman & Renshaw and H.C. Wainwright maintained Buy ratings on the shares. Rodman & Renshaw raised its price target to $17.50 while H.C. Wainwright kept its target at $23.00. Each firm pointed to landmark analyses referenced by the company that showed an early treatment benefit during the active dosing period, although those observations did not alter the outcome on the primary endpoint.
The selloff was strikingly company-specific. Major U.S. equity gauges moved higher on the session: the S&P 500 gained 1.5%, the Dow Jones rose 1.1% and the NASDAQ advanced 2.4%. Against that risk-on backdrop, Elicio's decline stood out, underscoring that the price action reflected firm-level developments rather than broader market weakness.
By the close of the session, the shares had fallen to $4.09, marking the stock's lowest level in 52 weeks. Market participants attributed the move to the intersection of an important clinical miss, an imbalance in baseline characteristics that raised questions about trial randomization, and a limited cash runway that increases the likelihood of future capital raises or partner-dependent progress.
Summary of the situation
- Elicio's Phase 2 AMPLIFY-7P study did not meet its pre-specified primary endpoint of disease-free survival in the intent-to-treat population.
- The 144-patient trial enrolled across 24 U.S. sites compared ELI-002 7P to observation after standard locoregional therapy.
- Investors reacted strongly, driving the stock to a one-year low amid concerns about trial balance and company funding.
Context provided by analysts
- Rodman & Renshaw and H.C. Wainwright retained Buy ratings and highlighted analyses showing early benefit during active dosing, with price targets of $17.50 and $23.00 respectively.